|Videos|October 6, 2020
Dr. Lonial Discusses Ongoing Research With BiTEs and CAR T-Cell Therapy in Myeloma
Author(s)Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.
Advertisement
Sagar Lonial, MD, FACP, professor and chair in the Department of Hematology and Medical Oncology of Emory University School of Medicine and chief medical officer of Winship Cancer Institute of Emory University, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas
5